

EOSINOPENIA:

An early, effective, and relevant COVID-19 biomarker?

Elena Roca ^a, Laura Ventura ^c, Costanza M. Zattra ^a, Carlo Lombardi ^b

a. COVID-19 Unit, Departmental Unit, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.

b. COVID-19 Unit & Departmental Unit of Pneumology & Allergology, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy.

c. Department of Statistical Sciences, University of Padova, Padova, Italy.

Elena Roca: rocaelena@gmail.com

Laura Ventura: ventura@stat.unipd.it

Costanza Maria Zattra: c.zattra@unibs.it

Carlo Lombardi: carlo.lombardi@poliambulanza.it

Corresponding Author:

Elena Roca MD

Covid-19 Unit, Head and Neck Department, Poliambulanza Foundation Hospital

Via Leonida Bissolati, 57, 25124 Brescia

Brescia (Italy)

Phone: +39 3393667949

Keywords: Eosinopenia, SARS-CoV2, COVID-19 disease

Word count: 479

References: 8

Tables: 1

Figures. 0

Financial disclosures: none

Authorship: all authors cared for the patient and contributed to the manuscript.

Conflict of interest: none to declare

Role of funding source and ethics committee approval: not applicable

Dear Editor,

we have read with interest the article of Lippi et Al. "Eosinophil count in severe coronavirus disease 2019 (COVID-19)" (1). The Authors argue that there is an association between eosinophil count and Covid-19, but that eosinopenia appears not to be associated with the unfavourable progression of the disease.

Actually there are not a lot of studies about this topic and those that exist relate to Chinese case series.

We report our case history relating to patients admitted to our Covid-19 Unit in our hospital in Brescia, one of the Northern Italian cities most affected by the SARS-Cov-2.

Eosinophils originate from CD34+stem cells in the bone marrow as terminally differentiated cells; in fact they no longer proliferate once formed (2,3). Under physiological conditions, the eosinophil count only covers a small percentage of circulating leukocytes, about 1-3%, but their levels may vary in different conditions (4).

In the MERS-CoV, like in Covid-19, was demonstrated that patients had extensive inflammatory cellular infiltrates in the interstitium and alveoli (5) and, furthermore, they contribute to lung damage

as they compromise lung function too (2). Consequently, some authors speculated that probably neutrophils, eosinophils, macrophages and lymphocytes migrate from peripheral blood into the lung tissue, causing neutropenia, eosinopenia lymphopenia (6).

Also in Italian patients admitted to our Unit it was shown a significant decrease in circulating eosinophils. In the 294 patients (M/F = 88/206; age range: 24-95 yrs; mean age: 68.8 yrs) admitted to our Unit, the median value of eosinophil count was $0.01 \times 10^9/L$ (mean 0.028, SD \pm 0.04). Moreover, it was shown that in 246 patients (83.7%) there was a decrease in circulating eosinophils (eosinophils $< 0.05 \times 10^9/L$). Eosinophil count was correlated with active smoking (p-value=0.04), chronic obstructive pulmonary disease (COPD) (p-value=0.037), haemoglobin levels (p-value=0.016), White Blood Cells (p-value <0.01) and platelets (p-value <0.01) counts.

The Welch two sample t-test showed that the mean value of eosinophil was significantly smaller in deceased patients (p-value = 0.032); the ANOVA analysis indicated also that eosinopenia had a weak association with the unfavorable progression of the disease (p-value = 0.049) (**table 1**).

Some Authors have also speculated that the improvement of eosinopenia may be an indicator of COVID-19 improvement too, but more data will be needed to confirm this (7,8).

In conclusion we think that the data obtained from our study confirm that the evaluation of the eosinophilic blood count represents a valid biomarker: the presence of eosinopenia can aid in early diagnosis of COVID-19 and it may be a useful tool in deciding whether to promptly isolate a patient and initiate specific therapies while waiting for confirmatory test results. Furthermore, persistent eosinopenia after admission correlated with prognostic evolution (high disease severity and low rates of recovery). Finally, Influenza pneumonia and COVID-19 are two different types of respiratory viral pneumonia with very similar clinical manifestations, but eosinopenia may not be typically observed in patients with influenza pneumonia.

Table 1: Significant relationship between eosinophil count and status and severity.

STATUS	DEATH	mean = 0.022 (sd = 0.03)	Welch t-test p = 0.032
	ALIVE	mean = 0.031 (sd = 0.05)	
SEVERITY	0	mean = 0.025 (sd = 0.03)	Kruskal-Wallis test p = 0.049
	1	mean = 0.032 (sd = 0.05)	
	2	mean = 0.019 (sd = 0.02)	

Legend: 0 Mild: no oxygen; 1 Moderate: nasal cannulas, oxygen mask; 2 Severe: NIV/BPAP/ intubation

REFERENCES

1. Lippi G, Henry BM. Eosinophil count in severe coronavirus disease 2019 QJM: An International Journal of Medicine, Volume 113, Issue 7, July 2020, Pages 511–512.
2. Eltboli O, Brightling CE. Eosinophils as diagnostic tools in chronic lung disease. *Expert. Rev. Respir. Med.* 7 (2013) 33–42.
3. Fulkerson PC, Rothenberg ME. Eosinophil development, disease involvement and therapeutic suppression *Adv. Immunol.* 138 (2018) 1–34.
4. Lombardi C, Passalacqua G. Eosinophilia and diseases: clinical revision of 1862 cases. *Arch Intern Med.* 2003 Jun 9;163(11):1371-3.
5. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, *Semin. Immunopathol.* 39 (2017) 529–539.
6. Da-Wei Sun, Dong Zhang, Run-Hui Tian, Yang Li, Yu-Shi Wang, Jie Cao. The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel? *Clin Chim Acta.* 2020 Sep;508:122-129. Epub 2020 May 14.
7. Fang Liu, Aifang Xu, Yan Zhang, Weiling Xuan, Tingbo Yan, Kenv Pan, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. *Int J Infect Dis.* 2020 Jun;95:183-191.
8. Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. *J Allergy Clin Immunol.* 2020 Jul;146(1):1-7. Epub 2020 Apr 25.